Vanda Pharmaceuticals Secures FDA Approval for NEREUS (Tradipitant), First New Motion Sickness Drug in Over 40 Years
The US FDA approved Vanda Pharmaceuticals' NEREUS (tradipitant), an oral NK-1 receptor antagonist, for preventing vomiting induced by motion.12
This is the first new pharmacologic treatment for motion sickness in more than 40 years.124
Efficacy supported by three pivotal clinical trials, including two Phase III studies (Motion Syros and Motion Serifos), showing significant reductions in vomiting.1
Affects 25-30% of adults; 5-15% experience severe symptoms.1
Vanda plans to launch NEREUS in the coming months.1
Approval followed FDA lifting a partial clinical hold on December 4.3
Sources:
1. https://manufacturingchemist.com/vanda-pharmaceuticals-fda-approval-motion-sickness-nereus
2. https://www.pharmexec.com/view/fda-approves-nereus-prevention-motion-induced-vomiting
3. https://www.fiercepharma.com/pharma/vandas-motion-sickness-drug-and-agios-thalassemia-treatment-make-grade-fda